ZyVersa files Section 205 petition to validate charter amendment after Boxed decision uncertainty

ZyVersa Therapeutics, Inc.

Filed petition in Delaware Chancery on March 9, 2023 seeking validation of Second Amended and Restated Certificate of Incorporation and all shares issued.
Uncertainty arose from Boxed decision questioning whether separate class vote was required for reduction of authorized shares from 220M to 110M.
Court granted expedited proceedings; final hearing set for March 29, 2023 at 11:00 a.m. ET.
Company had 9,211,922 shares outstanding as of petition date; all shares remain below authorized limits.
If validation not granted, could affect ability to raise capital and Nasdaq listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.